Anti-Müllerian hormone, β-catenin and Müllerian duct regression
- 15 December 2003
- journal article
- review article
- Published by Elsevier BV in Molecular and Cellular Endocrinology
- Vol. 211 (1-2), 115-121
- https://doi.org/10.1016/j.mce.2003.09.022
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Wnt signalling sees spotsNature, 2002
- Mullerian Inhibiting Substance Signaling Uses a Bone Morphogenetic Protein (BMP)-Like Pathway Mediated by ALK2 and Induces Smad6 ExpressionMolecular Endocrinology, 2001
- Insulin and IGF-1 stimulate the β-catenin pathway through two signalling cascades involving GSK-3β inhibition and Ras activationOncogene, 2001
- Platelet Endothelial Cell Adhesion Molecule-1 and Vascular Endothelial Cadherin Cooperatively Regulate Fibroblast Growth Factor-induced Modulations of Adherens Junction FunctionsJournal of Investigative Dermatology, 2001
- Engagement of Bone Morphogenetic Protein Type IB Receptor and Smad1 Signaling by Anti-Müllerian Hormone and Its Type II ReceptorPublished by Elsevier BV ,2000
- WNT-1 and HGF Regulate GSK3β Activity and β-Catenin Signaling in Mammary Epithelial CellsBiochemical and Biophysical Research Communications, 1998
- Developmental expression of a candidate mullerian inhibiting substance type II receptorEndocrinology, 1996
- Disruption of epithelial cell-matrix interactions induces apoptosisThe Journal of cell biology, 1994
- Effect of human recombinant mullerian inhibiting substance on isolated epithelial and mesenchymal cells during mullerian duct regression in the ratEndocrinology, 1992
- The epithelial-mesenchymal interface of the male rat Mullerian duct: Loss of basement membrane integrity and ductal regressionDevelopmental Biology, 1982